211 related articles for article (PubMed ID: 14769027)
21. Elucidation of the structural basis for the slow reactivity of thrombin with plasminogen activator inhibitor-1.
Rezaie AR
Biochemistry; 1998 Sep; 37(38):13138-42. PubMed ID: 9748320
[TBL] [Abstract][Full Text] [Related]
22. Recombinant plasminogen activator inhibitor type 1: a review of structural, functional, and biological aspects.
Reilly TM; Mousa SA; Seetharam R; Racanelli AL
Blood Coagul Fibrinolysis; 1994 Feb; 5(1):73-81. PubMed ID: 8180342
[TBL] [Abstract][Full Text] [Related]
23. Effects of Phe-to-Trp mutation and fluorotryptophan incorporation on the solution structure of cardiac troponin C, and analysis of its suitability as a potential probe for in situ NMR studies.
Wang X; Mercier P; Letourneau PJ; Sykes BD
Protein Sci; 2005 Sep; 14(9):2447-60. PubMed ID: 16131667
[TBL] [Abstract][Full Text] [Related]
24. Proteinase specificity and functional diversity in point mutants of plasminogen activator inhibitor 1.
Gils A; Declerck PJ
J Biol Chem; 1997 May; 272(19):12662-6. PubMed ID: 9139722
[TBL] [Abstract][Full Text] [Related]
25. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation.
Nar H; Bauer M; Stassen JM; Lang D; Gils A; Declerck PJ
J Mol Biol; 2000 Mar; 297(3):683-95. PubMed ID: 10731421
[TBL] [Abstract][Full Text] [Related]
26. The importance of helix F in plasminogen activator inhibitor-1.
Vleugels N; Gils A; Bijnens AP; Knockaert I; Declerck PJ
Biochim Biophys Acta; 2000 Jan; 1476(1):20-6. PubMed ID: 10606763
[TBL] [Abstract][Full Text] [Related]
27. Effect of stabilizing versus destabilizing interactions on plasminogen activator inhibitor-1.
Vleugels N; Leys J; Knockaert I; Declerck PJ
J Pharm Belg; 2000; 55(2):57-8. PubMed ID: 10842928
[TBL] [Abstract][Full Text] [Related]
28. Probing local environments of tryptophan residues in proteins: comparison of 19F nuclear magnetic resonance results with the intrinsic fluorescence of soluble human tissue factor.
Zemsky J; Rusinova E; Nemerson Y; Luck LA; Ross JB
Proteins; 1999 Dec; 37(4):709-16. PubMed ID: 10651284
[TBL] [Abstract][Full Text] [Related]
29. Atomic mutations at the single tryptophan residue of human recombinant annexin V: effects on structure, stability, and activity.
Minks C; Huber R; Moroder L; Budisa N
Biochemistry; 1999 Aug; 38(33):10649-59. PubMed ID: 10451359
[TBL] [Abstract][Full Text] [Related]
30. Distortion of the catalytic domain of tissue-type plasminogen activator by plasminogen activator inhibitor-1 coincides with the formation of stable serpin-proteinase complexes.
Perron MJ; Blouse GE; Shore JD
J Biol Chem; 2003 Nov; 278(48):48197-203. PubMed ID: 14500731
[TBL] [Abstract][Full Text] [Related]
31. Functional effects of single amino acid substitutions in the region of Phe113 to Asp138 in the plasminogen activator inhibitor 1 molecule.
Sui GC; Wiman B
Biochem J; 1998 Apr; 331 ( Pt 2)(Pt 2):409-15. PubMed ID: 9531478
[TBL] [Abstract][Full Text] [Related]
32. [Plasminogen activator-inhibitor 1: biochemical, structural and functional studies].
Declerck P
Verh K Acad Geneeskd Belg; 1993; 55(5):457-73. PubMed ID: 8128782
[TBL] [Abstract][Full Text] [Related]
33. Effect of stabilizing versus destabilizing interactions on plasminogen activator inhibitor-1.
Vleugels N; Leys J; Knockaert I; Declerck PJ
Thromb Haemost; 2000 Nov; 84(5):871-5. PubMed ID: 11127870
[TBL] [Abstract][Full Text] [Related]
34. Comparison of C40/82A and P27A C40/82A barstar mutants using 19F NMR.
Li H; Frieden C
Biochemistry; 2007 Apr; 46(14):4337-47. PubMed ID: 17371049
[TBL] [Abstract][Full Text] [Related]
35. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
[TBL] [Abstract][Full Text] [Related]
36. Characterization of a small molecule PAI-1 inhibitor, ZK4044.
Liang A; Wu F; Tran K; Jones SW; Deng G; Ye B; Zhao Z; Snider RM; Dole WP; Morser J; Wu Q
Thromb Res; 2005; 115(4):341-50. PubMed ID: 15668194
[TBL] [Abstract][Full Text] [Related]
37. A concerted structural transition in the plasminogen activator inhibitor-1 mechanism of inhibition.
Blouse GE; Perron MJ; Thompson JH; Day DE; Link CA; Shore JD
Biochemistry; 2002 Oct; 41(40):11997-2009. PubMed ID: 12356300
[TBL] [Abstract][Full Text] [Related]
38. Variants of tissue-type plasminogen activator that display extraordinary resistance to inhibition by the serpin plasminogen activator inhibitor type 1.
Tachias K; Madison EL
J Biol Chem; 1997 Jun; 272(23):14580-5. PubMed ID: 9169416
[TBL] [Abstract][Full Text] [Related]
39. Incorporation of tryptophan analogues into staphylococcal nuclease, its V66W mutant, and Delta 137-149 fragment: spectroscopic studies.
Wong CY; Eftink MR
Biochemistry; 1998 Jun; 37(25):8938-46. PubMed ID: 9636035
[TBL] [Abstract][Full Text] [Related]
40. Tryptophan mutants of cardiac troponin C: 3D structure, troponin I affinity, and in situ activity.
Julien O; Sun YB; Wang X; Lindhout DA; Thiessen A; Irving M; Sykes BD
Biochemistry; 2008 Jan; 47(2):597-606. PubMed ID: 18092822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
